Clinical Trial Update: Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cardio protective effects of an SGLT2 inhibitor in hemodialysis patients and its impact on quality of life; currently active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: Al-Azhar University | Conditions: Kidney Diseases | Phase 3 | Status: ACTIVE_NOT_RECRUITING